BACKGROUND: Whereas some studies have shown clear evidence for an augmentation effect of D-cycloserine (DCS) on exposure therapy for anxiety disorders, other studies have shown weak effects or no effect at all. Some preclinical data suggest that the DCS augmentation effect is moderated by the success of extinction learning. Therefore, we conducted a reanalysis of existing data to examine whether the effects of DCS on clinical outcome would vary as a function of response to the exposure session (i.e., exposure success). METHODS: In a clinical trial, patients with height phobia received two sessions involving 30 minutes of virtual reality exposure therapy and were randomly assigned to a pill placebo (n = 14) or 50 mg of DCS (n = 15) immediately after each session. RESULTS: Mixed-effects regression analysis showed that the effects of DCS administration on clinical improvement was moderated by the level of fear experienced just before concluding exposure sessions. Patients receiving DCS exhibited significantly greater improvement in symptoms relative to patients who received placebo when fear was low at the end of the exposure. In contrast, when end fear was still elevated, patients receiving DCS improved less compared with those receiving placebo. CONCLUSIONS: D-cycloserine appears to enhance the benefits of exposure treatment when applied after a successful session, but it seems to have detrimental effects when administered after inadequate/unsuccessful exposure sessions.
RCT Entities:
BACKGROUND: Whereas some studies have shown clear evidence for an augmentation effect of D-cycloserine (DCS) on exposure therapy for anxiety disorders, other studies have shown weak effects or no effect at all. Some preclinical data suggest that the DCS augmentation effect is moderated by the success of extinction learning. Therefore, we conducted a reanalysis of existing data to examine whether the effects of DCS on clinical outcome would vary as a function of response to the exposure session (i.e., exposure success). METHODS: In a clinical trial, patients with height phobia received two sessions involving 30 minutes of virtual reality exposure therapy and were randomly assigned to a pill placebo (n = 14) or 50 mg of DCS (n = 15) immediately after each session. RESULTS: Mixed-effects regression analysis showed that the effects of DCS administration on clinical improvement was moderated by the level of fear experienced just before concluding exposure sessions. Patients receiving DCS exhibited significantly greater improvement in symptoms relative to patients who received placebo when fear was low at the end of the exposure. In contrast, when end fear was still elevated, patients receiving DCS improved less compared with those receiving placebo. CONCLUSIONS:D-cycloserine appears to enhance the benefits of exposure treatment when applied after a successful session, but it seems to have detrimental effects when administered after inadequate/unsuccessful exposure sessions.
Authors: Adam J Guastella; Rick Richardson; Peter F Lovibond; Ronald M Rapee; Jonathan E Gaston; Philip Mitchell; Mark R Dadds Journal: Biol Psychiatry Date: 2008-01-07 Impact factor: 13.382
Authors: Michael W Otto; David F Tolin; Naomi M Simon; Godfrey D Pearlson; Shawnee Basden; Suzanne A Meunier; Stefan G Hofmann; Katherine Eisenmenger; John H Krystal; Mark H Pollack Journal: Biol Psychiatry Date: 2009-10-06 Impact factor: 13.382
Authors: Eric A Storch; Lisa J Merlo; Michael Bengtson; Tanya K Murphy; Mark H Lewis; Mark C Yang; Marni L Jacob; Michael Larson; Adam Hirsh; Melanie Fernandez; Gary R Geffken; Wayne K Goodman Journal: Int Clin Psychopharmacol Date: 2007-07 Impact factor: 1.659
Authors: Sabine Wilhelm; Ulrike Buhlmann; David F Tolin; Suzanne A Meunier; Godfrey D Pearlson; Hannah E Reese; Paul Cannistraro; Michael A Jenike; Scott L Rauch Journal: Am J Psychiatry Date: 2008-02-01 Impact factor: 18.112
Authors: Michael W Otto; M Alexandra Kredlow; Jasper A J Smits; Stefan G Hofmann; David F Tolin; Rianne A de Kleine; Agnes van Minnen; A Eden Evins; Mark H Pollack Journal: Biol Psychiatry Date: 2015-09-25 Impact factor: 13.382
Authors: Michael W Otto; Gladys N Pachas; Corinne Cather; Susanne S Hoeppner; Samantha J Moshier; Bridget A Hearon; Heather Burrell Ward; Alexandra B Laffer; Jasper A J Smits; A Eden Evins Journal: Cogn Behav Ther Date: 2018-08-16
Authors: Michael B VanElzakker; M Kathryn Dahlgren; F Caroline Davis; Stacey Dubois; Lisa M Shin Journal: Neurobiol Learn Mem Date: 2013-12-07 Impact factor: 2.877